Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Mola.tv transformiert Digital Rights Management in die Verimatrix Secure Cloud
Mola.tv transformiert Digital Rights Management in die Verimatrix Secure Cloud


Verimatrix, (Paris:VMX), ehemals bekannt als Inside Secure, ein globaler Anbieter von innovativen, kundenfreundlichen Cybersicherheitslösungen zum Schutz von Videoinhalten, Endgeräten, Software und

Cellectis to Hold Fourth Quarter and Full Year 2019 Earnings Call on Thursday, March 5, 2020 at 7:30 AM EST
Cellectis to Hold Fourth Quarter and Full Year 2019 Earnings Call on Thursday, March 5, 2020 at 7:30 AM EST


Regulatory News:



Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on

Mola.tv Takes Digital Rights Management into the Verimatrix Secure Cloud
Mola.tv Takes Digital Rights Management into the Verimatrix Secure Cloud


Regulatory News:



Verimatrix, (Paris:VMX), formerly known as Inside Secure, a global provider of innovative, customer-friendly cybersecurity solutions that protect video content, endpoint devices

Albaniens größter Videodienstanbieter TiBO setzt Verimatrix Multi-DRM für die Verwaltung Cloud-basierter digitaler Rechte ein
Albaniens größter Videodienstanbieter TiBO setzt Verimatrix Multi-DRM für die Verwaltung Cloud-basierter digitaler Rechte ein


Regulatorische Meldungen:



Verimatrix, (Paris:VMX) (Euronext Paris: VMX), ehemals bekannt als Inside Secure, ein globaler Anbieter von innovativen, kundenfreundlichen Cybersicherheitslösungen zum

Albania’s Largest Video Service Provider TiBO Deploys Verimatrix Multi-DRM For Cloud-based Digital Rights Management
Albania’s Largest Video Service Provider TiBO Deploys Verimatrix Multi-DRM For Cloud-based Digital Rights Management


Regulatory News:



Verimatrix, (Paris:VMX) (Euronext Paris: VMX), formerly known as Inside Secure, a global provider of innovative, customer-friendly cybersecurity solutions that protect video

Verimatrix und Qt Company präsentieren gemeinsam IoT-Shielding auf der Embedded World 2020
Verimatrix und Qt Company präsentieren gemeinsam IoT-Shielding auf der Embedded World 2020


Verimatrix, vormals bekannt als Inside Secure, ein global tätiger Anbieter von innovativen, kundenfreundlichen Cyber-Sicherheitslösungen zum Schutz von Video-Inhalten, Endgeräten, Software und

Verimatrix and Qt Company Join Forces at Embedded World 2020 to Showcase IoT Shielding
Verimatrix and Qt Company Join Forces at Embedded World 2020 to Showcase IoT Shielding


Verimatrix, (Paris:VMX), formerly known as Inside Secure, a global provider of innovative, customer-friendly cybersecurity solutions that protect video content, endpoint devices, software and

First Patient Dosed With Transgene’s Oncolytic Virus TG6002, Administered by Intrahepatic Artery Infusion in Colorectal Cancer With Liver Metastases
First Patient Dosed With Transgene’s Oncolytic Virus TG6002, Administered by Intrahepatic Artery Infusion in Colorectal Cancer With Liver Metastases


Regulatory News:



Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces that the first

Cellectis and Servier Expand Collaboration on UCART19 Products
Cellectis and Servier Expand Collaboration on UCART19 Products


Regulatory News:



Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic

ESI Group: Full-Year 2019 Sales
ESI Group: Full-Year 2019 Sales


Regulatory News:



ESI Group, Paris, France, (ISIN Code: FR0004110310, Symbol: ESI) (Paris:ESI), releases its sales for the financial year starting on February 1, 2019 and ending on December 31

MEDICREA® Announces FDA Clearance of the World’s First Patient-Matched Spinal Interbody Cages
MEDICREA® Announces FDA Clearance of the World’s First Patient-Matched Spinal Interbody Cages


MEDICREA® (Euronext Growth Paris : FR0004178572 – ALMED, PEA-PME eligible and OTCQX : MRNTF), pioneering the transformation of spinal surgery through Artificial Intelligence, predictive modeling

NANOBIOTIX Announces Fast Track Designation Granted By U.S. FDA For Investigation of First-in-class NBTXR3 In Head and Neck Cancer
NANOBIOTIX Announces Fast Track Designation Granted By U.S. FDA For Investigation of First-in-class NBTXR3 In Head and Neck Cancer


Regulatory News:



NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today

MEDICREA®’s UNiD® ASI Technology Hits 5,000th Patient-Specific Spine Surgery Milestone With Strong Penetration of the Degenerative and Minimally Invasive Market Segment
MEDICREA®’s UNiD® ASI Technology Hits 5,000th Patient-Specific Spine Surgery Milestone With Strong Penetration of the Degenerative and Minimally Invasive Market Segment


MEDICREA® (Euronext Growth Paris : FR0004178572 – ALMED, PEA-PME eligible and OTCQX : MRNTF), pioneering the transformation of spinal surgery through Artificial Intelligence, predictive modeling

Carbios Enters Joint Development Agreement With Novozymes to Produce Its Proprietary Enzyme for Complete Recycling of PET-plastics and Fibers
Carbios Enters Joint Development Agreement With Novozymes to Produce Its Proprietary Enzyme for Complete Recycling of PET-plastics and Fibers


Regulatory News:



CARBIOS (Euronext Growth Paris: ALCRB), a company pioneering new bio-industrial solutions to reinvent the lifecycle of plastic and textile polymers, announced today an exclusive

Carbios kündigt strategische Allianz mit dem Nationalen Institut für angewandte Wissenschaften von Toulouse (INSA) an
Carbios kündigt strategische Allianz mit dem Nationalen Institut für angewandte Wissenschaften von Toulouse (INSA) an


CARBIOS (Paris:ALCRB) (Euronext Growth Paris: ALCRB), ein französisches Unternehmen aus dem Bereich grüne Chemie mit Sitz in Clermont-Ferrand, gab heute eine strategische Allianz mit dem INSA

Carbios Announces Strategic Alliance with the National Institute of Applied Sciences of Toulouse (INSA)
Carbios Announces Strategic Alliance with the National Institute of Applied Sciences of Toulouse (INSA)


Regulatory News:



CARBIOS (Paris:ALCRB) (Euronext Growth Paris: ALCRB), a French green chemistry company based in Clermont-Ferrand, announced today a strategic alliance with INSA Toulouse through

First Patient Dosed with Cellectis’ New Allogeneic UCART123 Product Candidate for Relapsed/Refractory Acute Myeloid Leukemia
First Patient Dosed with Cellectis’ New Allogeneic UCART123 Product Candidate for Relapsed/Refractory Acute Myeloid Leukemia


Regulatory News:



Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on

MEDICREA® Reports 2019 Annual Sales
MEDICREA® Reports 2019 Annual Sales


The MEDICREA® Group (Euronext Growth Paris: FR0004178572 – ALMED ; OTCQX Best Market – MRNTF), pioneering the transformation of spinal surgery through Artificial Intelligence, predictive modeling

MEDICREA Announces Preliminary Discussions With U.S. Strategic Partners
MEDICREA Announces Preliminary Discussions With U.S. Strategic Partners


The MEDICREA® Group (Euronext Growth Paris: FR0004178572 – ALMED ; OTCQX Best Market – MRNTF), pioneering the transformation of spinal surgery through Artificial Intelligence, predictive modeling

AKKA Launches a Recommended Voluntary Cash Offer on Data Respons ASA at NOK 48 Per Share
AKKA Launches a Recommended Voluntary Cash Offer on Data Respons ASA at NOK 48 Per Share


Regulatory News:



Following the announcement on 19 December 2019 to acquire Data Respons, AKKA Technologies SE (Paris:AKA) (BSE:AKA) (ISIN:FR0004180537), European leader in digital engineering

NANOBIOTIX Announces Plan for Global Phase III Head and Neck Cancer Registration Trial Along With Overall Development Update
NANOBIOTIX Announces Plan for Global Phase III Head and Neck Cancer Registration Trial Along With Overall Development Update


Regulatory News:



“After the achievement of major development milestones in 2019, 2020 offers great opportunity for Nanobiotix and NBTXR3 to fulfill unmet patient needs across oncology. Given

Farasis Energy gelingt mit Virtual Prototyping von ESI der Durchbruch auf dem Elektrofahrzeugmarkt
Farasis Energy gelingt mit Virtual Prototyping von ESI der Durchbruch auf dem Elektrofahrzeugmarkt


Die ESI Group (Paris:ESI), führender Innovator rund um Virtual Prototyping Software und Services für die Fertigungsindustrie, hat den chinesisch-amerikanischen Batteriehersteller Farasis Energy

Farasis Energy Breaks Through the Electric Vehicle Market Thanks to ESI’s Virtual Prototyping
Farasis Energy Breaks Through the Electric Vehicle Market Thanks to ESI’s Virtual Prototyping


ESI Group (Paris:ESI), leading innovator in Virtual Prototyping
software and services for manufacturing industries, helped Farasis
Energy, a Chinese-American battery provider,

Transgene and NEC Start Two Clinical Trials with TG4050, an Individualized AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers
Transgene and NEC Start Two Clinical Trials with TG4050, an Individualized AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers


Regulatory News:



Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TSE:

Cellectis: An Expert Review on Allogeneic CAR-T for Cancer Published in Nature Reviews Drug Discovery
Cellectis: An Expert Review on Allogeneic CAR-T for Cancer Published in Nature Reviews Drug Discovery


Cellectis
(Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth:ALCLS; Nasdaq:CLLS), a
biopharmaceutical company focused on developing immunotherapies based on
gene-edited